Phase I trial of SAR 101099.
Latest Information Update: 15 Feb 2012
At a glance
- Drugs SAR 101099 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- 15 Feb 2012 New trial record
- 31 Dec 2011 Status changed from recruiting to discontinued.